Krystal Biotech (KRYS) Receivables - Net (2023 - 2025)
Krystal Biotech (KRYS) has disclosed Receivables - Net for 3 consecutive years, with $127.4 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 21.63% to $127.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.4 million through Dec 2025, up 21.63% year-over-year, with the annual reading at $127.4 million for FY2025, 21.63% up from the prior year.
- Receivables - Net hit $127.4 million in Q4 2025 for Krystal Biotech, down from $129.6 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $129.6 million in Q3 2025 to a low of $9.3 million in Q3 2023.
- Historically, Receivables - Net has averaged $93.3 million across 3 years, with a median of $104.0 million in 2024.
- Biggest five-year swings in Receivables - Net: surged 944.42% in 2024 and later dropped 1.42% in 2025.
- Year by year, Receivables - Net stood at $42.0 million in 2023, then soared by 149.16% to $104.7 million in 2024, then rose by 21.63% to $127.4 million in 2025.
- Business Quant data shows Receivables - Net for KRYS at $127.4 million in Q4 2025, $129.6 million in Q3 2025, and $111.4 million in Q2 2025.